These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17694325)

  • 1. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.
    Hinz S; Kempkensteffen C; Christoph F; Hoffmann M; Krause H; Schrader M; Schostak M; Miller K; Weikert S
    J Cancer Res Clin Oncol; 2008 Mar; 134(3):331-6. PubMed ID: 17694325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas.
    Weikert S; Christoph F; Köllermann J; Müller M; Schrader M; Miller K; Krause H
    Int J Mol Med; 2005 Aug; 16(2):349-53. PubMed ID: 16012774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
    Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder.
    Hinz S; Kempkensteffen C; Weikert S; Schostak M; Schrader M; Miller K; Christoph F
    Tumour Biol; 2007; 28(3):151-7. PubMed ID: 17541304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
    Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
    Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth.
    Hwang CF; Huang HY; Chen CH; Chien CY; Hsu YC; Li CF; Fang FM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):597-604. PubMed ID: 21300475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance.
    Hinz S; Kempkensteffen C; Christoph F; Krause H; Schrader M; Schostak M; Miller K; Weikert S
    Tumour Biol; 2008; 29(5):323-9. PubMed ID: 18984978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
    Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
    J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines.
    Zhang YB; Niu HT; Chang JW; Dong GL; Ma XB
    Eur J Cancer Care (Engl); 2011 Jan; 20(1):106-12. PubMed ID: 20148941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
    Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
    Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.
    Martínez-Fernández M; Dueñas M; Feber A; Segovia C; García-Escudero R; Rubio C; López-Calderón FF; Díaz-García C; Villacampa F; Duarte J; Gómez-Rodriguez MJ; Castellano D; Rodriguez-Peralto JL; de la Rosa F; Beck S; Paramio JM
    Oncotarget; 2015 Dec; 6(39):42258-75. PubMed ID: 26517683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
    Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
    Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.
    Wang H; Albadine R; Magheli A; Guzzo TJ; Ball MW; Hinz S; Schoenberg MP; Netto GJ; Gonzalgo ML
    Urol Oncol; 2012; 30(4):428-33. PubMed ID: 21396836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
    Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
    Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
    Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
    Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
    Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
    Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
    Cho KS; Oh HY; Lee EJ; Hong SJ
    Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
    Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
    Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of EZH2 and ARID1A expression in urothelial carcinoma: an immunohistochemical study.
    Sameh R; Mostafa N; Ramadan M; AbdelRaouf S; Abdelwahab K
    J Histotechnol; 2022 Mar; 45(1):21-28. PubMed ID: 34493171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.